GLP-1 agonist Wegovy (semaglutide) brought in DKK 17.3 billion ($2.49 billion) in the period, restoring earlier levels of ...
The recent success of drug therapies such as semaglutide and tirzepatide has fueled obesity research. In a phase 2 trial that enrolled patients with type 2 diabetes (ClinicalTrials.gov Identifier: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback